Ultimately, investigators found a significant reduction in ischemic stroke risk with asundexian compared to placebo, both in combination with antiplatelet therapy. Additionally, participants had no ...

TAIPEI (Taiwan News) — Taiwan's Lumosa Therapeutics Co. announced Thursday that it has received written guidance from the US ...

Argenica Therapeutics has taken a step forward in the development of its neuroprotective drug candidate ARG-007 in acute ...

Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major ...

The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate ...

Stroke and heart attack are life-threatening conditions that require emergency medical attention, but they differ in the affected organ and symptoms.

Once-daily asundexian 50 mg, on top of antiplatelet therapy, reduced risk for recurrent ischemic stroke after a ...

COVID-19 infection is associated with ischemic and hemorrhagic spinal stroke, with distinct clinical characteristics and underlying mechanisms.

Asundexian is designed to reduce thrombus formation without increasing bleeding risk by selectively inhibiting FXIa.

Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges ...

Bayer’s asundexian meets primary efficacy and safety endpoints in landmark phase III OCEANIC-STROKE study in secondary stroke prevention: Berlin Tuesday, November 25, 2025, 11:0 ...

Left atrial appendage occlusion (LAAO) during cardiac surgery in patients with atrial fibrillation was associated with lower ...